소아 염증성 장 질환 관리에 있어 원발성 경화성 담관염의 유무와 관계없이 경구 반코마이신 치료를 고려할 때인가?

Samyn et al. (Tue,)이 이 질문을 연구했습니다.

www.synapsesocial.com/papers/69d8968f6c1944d70ce08176 — DOI: https://doi.org/10.1002/jpn3.70431

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Effectiveness and safety of oral vancomycin in non‐primary sclerosing cholangitis paediatric inflammatory bowel disease· 2025 · 1 citations
2. Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (<scp>PSC‐IBD</scp>): A matched analysis from the Paediatric <scp>PSC</scp> Consortium· 2024 · 34 citations
3. Oral Vancomycin and Gentamicin for Treatment of Very Early Onset Inflammatory Bowel Disease· 2017 · 34 citations
4. Systematic review with meta‐analysis: the management of chronic refractory pouchitis with an evidence‐based treatment algorithm· 2016 · 120 citations
5. How frequent are vancomycin-resistant enterococci in patients with primary sclerosing cholangitis and ulcerative colitis treated with oral vancomycin?· 2022 · 15 citations